Compared with the control, substantially reduced arthritis scores (Fig. 5A), and CRP levels (Fig. 5B), with improvements in histology (Fig. 5C) and bone erosion scores (Fig. 5D), were observed with a dose of 20 mg/kg of olokizumab. Here, CRP is linked to arthritic joint disease.